Objective:To analyze the effect of methotrexate (MTX) combined with iguratimod (IT) in the treatment of refractory rheumatoid arthritis (RA). Methods:A total of 120 patients with refractory RA admitted to our hospital from July 2019 to December 2022 were selected as the research objects. According to different treatment methods,they were divided into group Ⅰ(40 patients),group M (40 patients) and group IM (40 patients). Group Ⅰ was treated with IT,group M was treated with MTX,and group IM was treated with MTX+IT. The clinical efficacy,improvement of joint symptoms (joint pain rate,joint swelling rate,morning stiffness time) and bone metabolism indexes[25(OH)D,TPINP]were compared among the three groups. Results:After treatment,the total effective rate of IM group was higher than that of Ⅰ group and M group (P<0.05). The joint pain rate and joint swelling rate in the IM group were lower than those in the Ⅰ group and the M group,and the morning stiffness time was shorter than that in the Ⅰ group and the M group (P<0.05). The levels of 25 ( OH ) D and TPINP in IM group were better than those in Ⅰ group and M group (P<0.05). Conclusion:The clinical efficacy of MTX combined with IT in the treatment of refractory RA is satisfactory,which can significantly improve the joint symptoms and bone metabolism indexes of patients,and is worthy of clinical application.
维普
万方数据